PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | NEJM
Cureus | Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy | Article
PIONEER AF-PCI: Rivaroxaban + P2Y12 Inhibitor clopidogrel ~94% or Rivaroxaban + DAPT vs. Warfarin + DAPT in Patients with Atrial
Studio PIONEER AF-PCI nei pazienti con fibrillazione atriale sottoposti ad angioplastica coronarica: quali risvolti clinici? - ATBV
Xarelto® (rivaroxaban) – PIONEER
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy (Transcript)
How will PIONEER-AF change our practice? - ppt download
Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials
![臨床藥學] PIONEER AF-PCI：心房顫動合併冠心症接受心導管治療，Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS](https://4.bp.blogspot.com/-ki6zrPeBWxI/WCpzKF9yAbI/AAAAAAABXc4/evvkGYfo10QidY4RLi4YXaODj2ZOT5-hgCLcB/s1600/NEJS%2B20160905.png "臨床藥學] PIONEER AF-PCI：心房顫動合併冠心症接受心導管治療，Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS")
臨床藥學] PIONEER AF-PCI：心房顫動合併冠心症接受心導管治療，Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review - ScienceDirect
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | Challenges in Cardiology
3 0 Patients undergoing PCI with atrial fibrillation AF
Pionner af pci
Antithrombotic Strategy in Patients With AF and Recent ACS or PCI: Primary Results of the AUGUSTUS Trial - American College of Cardiology
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy | Circulation
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis | Open Heart
The PIONEER AF-PCI study: its implications for everyday practice in the UK - The British Journal of Cardiology
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
New Perspectives in AF and PCI: Implications for the Practicing Physician. - ppt download
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
Prevention of Bleeding in Patients With Atrial Fibrillation Undergoing PCI ( PIONEER): Three May End Up Being a Crowd - Samuel A. Berkman, 2018
![PDF] Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF](https://d3i71xaburhd42.cloudfront.net/4107965fd29bd24ad0a28eea66938425b733e805/4-TableI-1.png "PDF] Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF")